Jointly provided by The France Foundation and the Kidney Cancer Association.

Target Audience

This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

Statement of Need

Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates and researchers to help promote learning and collaboration for advancement in the renal cancer space.

Educational Activity Learning Objectives

Upon completion of this course, the participants should be able to:

  1. Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma 
  2. Identify the novel approaches to non-clear RCC patient management 
  3. Understand the role of the tumor microenvironment in kidney cancer 
  4. Discuss how to design biomarker driven clinical trials in kidney cancer 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The France Foundation designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ethics: This course has been designated for 0.75 credit(s) of education in medical ethics and/or professional responsibility. 

Method of Participation/How to Receive Credit

  1. Review the activity objectives and CME/CE information.
  2. Participate in the CME/CE activity.
  3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the Kidney Cancer Association who control content have no relevant financial relationships to disclose.

Faculty Disclosures

Faculty disclosures will be provided prior to the start of the activity.

Disclosure of Unlabeled Use

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation and the Kidney Cancer Association present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the Kidney Cancer Association assume no liability for the information herein.